

The genomic application that streamlines the interpretation of complex variants by combining the DNA target capture and RNA target enrichment kits with the analytical performance and advanced features of the SOPHiA DDM™ Platform.

Main Features

SOPHiA DDM™ Myeloid Plus Solution (MYS+) covers **30 relevant genes** (10 with complete coding sequences) associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. Probe design is optimized to guarantee high on-target rate and coverage uniformity even in GC-rich regions. The RNA part covers **119 gene** fusions associated with leukemia. The technical limitations related to the analyses of translocations and key biomarkers such as *CEBPA*, *CALR* and *FLT3* (including detection of internal tandem duplications) are addressed.

DNA Gene Panel	Variants Called	Recommendations	Wet Lab
<i>ABL1</i> (4-9), <i>ASXL1</i> (10,12,13), <i>BRAF</i> (15), <i>CALR</i> (9), <i>CBL</i> (8,9), <i>CEBPA</i> (<i>all</i>), <i>CSF3R</i> (<i>all</i>), <i>DNMT3A</i> (<i>all</i>), <i>ETV6</i> (<i>all</i>), <i>EZH2</i> (<i>all</i>), <i>FLT3</i> (13-15,20), <i>HRAS</i> (2,3), <i>IDH1</i> (4), <i>IDH2</i> (4), <i>JAK2</i> (<i>all</i>), <i>KIT</i> (2,8-11,13,17,18), <i>KRAS</i> (2,3), <i>MPL</i> (10), <i>NPM1</i> (10,11), <i>NRAS</i> (2,3), <i>PTPN11</i> (3,7-13), <i>RUNX1</i> (<i>all</i>), <i>SETBP1</i> (4), <i>SF3B1</i> (10-16), <i>SRSF2</i> (1), <i>TET2</i> (<i>all</i>), <i>TP53</i> (<i>all</i>), <i>U2AF1</i> (2,6), <i>WT1</i> (6-10), <i>ZRSR2</i> (<i>all</i>)	SNVs Indels CNVs <i>FLT3</i> ITDs Gene fusion	Starting material 50 ng DNA, 500 ng RNA Sample type Blood and bone marrow Samples per run / Sequencer¹ 24 DNA + 24 RNA on Illumina MiSeq® v3 (2x300bp) 12 DNA + 12 RNA on Illumina MiSeq® v2 (2x250bp)	Day 1: DNA and RNA Library Preparation Day 2: Capture and Sequencing of DNA and RNA libraries in 1 run Total library preparation time: 2 days for DNA, 6 hours for RNA
RNA Gene Fusion Panel			

Analytical Performance

The SOPHiA DDM™ Platform analyzes complex NGS data by detecting, annotating and pre-classifying genomic alterations and RNA fusions in the genes of this panel.

Analysis time from FASTQ: from 4 hours²

	Observed (%)	Lower 95% CI
Sensitivity	99.92	97.49
Specificity	99.99	99.98
Accuracy	99.99	99.98
Precision	99.52	91.47
Repeatability	98.69	98.66
Reproducibility	99.30	99.27
Average on-target rate	87.41	
Coverage uniformity	99.98	
Mean % of target region > 1000x	> 99	
Limit of detection	2.5 [*]	

The SOPHiA DDM™ Platform reaches advanced analytical performance. Performance values are based on SNVs and Indels in 237 DNA samples processed on Illumina MiSeq®.
^{*}For SNVs and Indels; *FLT3*-ITD excepted.

One Simple Intuitive Platform: Beyond Analytics

Accelerated assessment and reporting of genomic variants

The platform helps users to immediately focus on relevant genomic alterations. Several features facilitate their interpretation process:

- Hotspot screening
- Algorithm-supported variant pre-classification
- Fully customizable filters
- Comprehensive report

Product code:

BS0112ILLRSMY10³

Confident decision-making

The OncoPortal™ Plus add-on module for SOPHiA DDM™ Platform matches tumor molecular profiles with clinical associations and available clinical trials, leveraging expertly curated evidence powered by JAX-CKB. After interpretation, the flexible reporting tools enable users to prepare push-button, comprehensive reports that are customizable to their needs.

Global support at every step

We offer local support anywhere in the world. Our dedicated bioinformaticians help save time and resources, ensuring fast resolution of workflow disruptions. In addition, our MaxCare Program provides assistance with assay set up for fast and worry-free transition to routine testing.

Access to the SOPHiA GENETICS Community

Through the SOPHiA DDM™ Platform genomics experts from hundreds of healthcare institutions interpret their findings and flag the pathogenicity level of variants. This highly valuable information enriches the variant knowledge base and is safely shared among the members of the community, supporting their decision-making process for research purposes.

CI, confidence interval; CNVs, copy number variations; Indels, insertions/deletions; ITDs, internal tandem duplications; NGS, next-generation sequencing; SNVs, single nucleotide variants.

1. Number of samples per run is recommended for 1000x coverage depth. Sequencing recommendations and specifications for other sequencing kits and instruments available upon request. Delivery time may vary according to the selected sequencing platform.
 2. Analysis time may vary depending on the number of samples multiplexed and server load.
 3. Product codes for SOPHiA GENETICS™ Universal Library Prep (ULP), replacing BS0112ILLRSMY10 and BS0112ILLRSMY01.

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB).

For Research Use Only. Not for Use in Diagnostic Procedures.

OncoPortal™ Plus is for Clinical Decision Support Use Only. Not intended as a primary diagnostic tool.

All third party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS' use of third party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third party trademarks is to identify the corresponding third party goods and/or services and shall be considered nominative fair use under the trademark law.

RNA Gene Fusion Panel

ATF7IP(13)-JAK2(9,11,13,15,17,18,19), BCR(1,4,6,7,12,13,14,19)-ABL1(2,3,4), BCR(1,4,6,7,12,13,14,19)-FGFR1(11), BCR(1,4,6,7,12,13,14,19)-JAK2(9,11,13,15,17,18,19), BCR(1,4,6,7,12,13,14,19)-PDGFRA(12), BMP2K(14,15)-ZNF384(2,3,4,7), CBFA2T3(10,11)-GLIS2(4,5), CBFB(4,5)-MYH11(29,30,31,32,33,34,35), CCDC6(1,7)-PDGFRB(9,11), CHIC2(3)-ETV6(2,3), CNTRL(38)-FGFR1(11), CREBBP(4,5,6,7)-ZNF384(2,3,4,7), CUX1(11)-FGFR1(11), DEK(9)-NUP214(17,18), EBF1(10,13,14,15)-JAK2(9,11,13,15,17,18,19), EBF1(10,13,14,15)-PDGFRB(9,11), EML1(18)-ABL1(2,3,4), EP300(6)-ZNF384(2,3,4,7), ETV6(4,5,6,7)-ABL1(2,3,4), ETV6(4,5,6,7)-ARNT(3), ETV6(4,5,6,7)-JAK2(9,11,13,15,17,18,19), ETV6(4,5,6,7)-NTRK3(14), ETV6(4,5,6,7)-NTRK3(15), ETV6(4,5,6,7)-PDGFRB(9,11), ETV6(4,5,6,7)-RUNX1(1), ETV6(4,5,6,7)-RUNX1(3), FGFR1OP(5,6,7)-FGFR1(11), FIP1L1(12)-PDGFRA(12), FOXP1(19)-ABL1(2,3,4), INPP5D(8)-ABL1(2,3,4), KAT6A(16)-CREBBP(2,3), KMT2A(8,9,10,11)-AFDN(2), KMT2A(8,9,10,11)-AFF1(4,5,6,11), KMT2A(8,9,10,11)-AFF3(7,8,12), KMT2A(8,9,10,11)-AFF4(4,5,6), KMT2A(8,9,10,11)-ARHGAP26(19), KMT2A(8,9,10,11)-ARHGEF12(11,12,13), KMT2A(8,9,10,11)-ARHGEF17(2,3,4,5), KMT2A(8,9,10,11)-C2CD3(13,14,15,17), KMT2A(8,9,10,11)-CBL(10), KMT2A(8,9,10,11)-CIP2A(17), KMT2A(8,9,10,11)-CREBBP(2,3), KMT2A(8,9,10,11)-DCPS(2), KMT2A(8,9,10,11)-ELL(2,3,6), KMT2A(8,9,10,11)-EPS15(2,6), KMT2A(8,9,10,11)-FOXO3(2), KMT2A(8,9,10,11)-KMT2A(2), KMT2A(8,9,10,11)-KNL1(12), KMT2A(8,9,10,11)-MAML2(2,3), KMT2A(8,9,10,11)-MAPRE1(2,4,6), KMT2A(8,9,10,11)-MLLT1(2,4,5,6,7), KMT2A(8,9,10,11)-MLLT10(5,7,10,12,17), KMT2A(8,9,10,11)-MLLT11(2), KMT2A(8,9,10,11)-MLLT3(4,5,6,9,10), KMT2A(8,9,10,11)-MLLT6(8,9,12), KMT2A(8,9,10,11)-NRIP3(2), KMT2A(8,9,10,11)-RARA(2), KMT2A(8,9,10,11)-SEP5(2), KMT2A(8,9,10,11)-SEPT6(2), KMT2A(8,9,10,11)-SEPT9(2), KMT2A(8,9,10,11)-SEPT9(2), KMT2A(8,9,10,11)-TET1(9), MEF2D(7)-CSF1R(12), MN1(1)-ETV6(2,3), MNX1(1)-ETV6(2,3), MYB(8)-GATA1(5), NCOR1(35)-LYN(8), NDE1(6)-PDGFRB(9,11), NPM1(4,6)-MLF1(3), NPM1(4,6)-RARA(2), NUP214(23,26,28,29,30,31,32,34)-ABL1(2,3,4), NUP98(10,11,12,13,14)-DDX10(6,7), NUP98(10,11,12,13,14)-HOXA9(1,2), NUP98(10,11,12,13,14)-KDM5A(27), NUP98(10,11,12,13,14)-NSD1(6), NUP98(10,11,12,13,14)-RAP1GDS1(2,3), NUP98(10,11,12,13,14)-TOP1(8), OFD1(21)-JAK2(9,11,13,15,17,18,19), P2RY8(1)-CRLF2(1), PAG1(8)-ABL2(3,5), PAX5(4)-ETV6(2,3), PAX5(4)-JAK2(9,11,13,15,17,18,19), PAX5(5)-ETV6(2,3), PAX5(5)-JAK2(9,11,13,15,17,18,19), PCM1(26,36)-JAK2(9,11,13,15,17,18,19), PDE4DIP(16)-PDGFRB(9,11), PICALM(17,18,19)-MLLT10(5,7,10,12,17), PML(3,6)-RARA(2), RANBP2(18)-ABL1(2,3,4), RBM15(1)-MKL1(4,5), RCSD1(2)-ABL1(2,3,4), RCSD1(3)-ABL1(2,3,4), RUNX1(3)-RUNX1T1(6), SET(7)-NUP214(17,18), SFPQ(9)-ABL1(2,3,4), SNX2(3)-ABL1(2,3,4), SPAG9(26)-JAK2(9,11,13,15,17,18,19), SPTBN1(4)-FLT3(14), SPTBN1(4)-PDGFRB(9,11), SSBP2(5,6,8,10,16)-CSF1R(12), SSBP2(5,6,8,10,16)-JAK2(9,11,13,15,17,18,19), STAT5B(15,16)-RARA(2), STIL(1)-TAL1(3,4,6), STRN(6)-PDGFRA(12), STRN3(8,9)-JAK2(9,11,13,15,17,18,19), TAF15(6,9)-ZNF384(2,3,4,7), TCF3(11,13,15,16,17)-HLF(4), TCF3(11,13,15,16,17)-PBX1(3), TERF2(8)-JAK2(9,11,13,15,17,18,19), TPM3(8)-PDGFRB(9,11), TPR(22,39)-FGFR1(11), TRIM24(9,10,11)-FGFR1(11), ZBTB16(3,4)-ABL1(2,3,4), ZBTB16(3,4)-RARA(2), ZC3HAV1(12)-ABL2(3,5), ZEB2(9)-PDGFRB(9,11), ZMIZ1(18)-ABL1(2,3,4), ZMYM2(17)-FGFR1(11)